Wednesday, 25 April 2018 - 19:04
  • it
  • de
  • en
  • fr

Atopic dermatitis

Novartis to acquire Ziarco Group

Novartis announced it entered into a definitive agreement for the acquisition of Ziarco Group Limited, a privately held company focused on developing novel treatments in dermatology. This acquisition will allow the Switzerland-based giant to add to its portfolio ZPL389, an…

FDA, OK for Eucrisa, Pfizer’s topical treatment for atopic dermatitis

Pfizer announced that FDA approved Eucrisa (crisaborole) ointment 2%. This is a novel non-steroidal topical PDE-4 (phosphodieterase-4) inhibitor for the treatment of mild-to-moderate atopic dermatitis in patients two years of age and older. The product is the first and only…

MAA for Sanofi/Regeneron’s Dupixent accepted in Europe

Sanofi and Regeneron Pharmaceuticals announced that EMA accepted for review the MAA (Marketing Authorization Application) for Dupixent (dupilumab) for the treatment of adult patients with moderate-to-severe atopic dermatitis who are candidates for systemic therapy. Dupixent, an investigational product, is a…

FDA, priority review for Sanofi/Regeneron’s dupilumab in atopic dermatitis

Sanofi and Regeneron Pharmaceuticals today announced that FDA has accepted for priority review the BLA (Biologics License Application) for dupilumab for the treatment of adult patients with inadequately controlled moderate-to-severe atopic dermatitis. The PDUFA (Prescription Drug User Fee Act) should…